Stockscreener 앱 받기
0.22%
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer (PFE) Stock: AI Cost-Cutting and Strong Dividend Attract Investors - parameter.io
How Do Investors Really Feel About Pfizer Inc? - Benzinga
Natixis Has $45.97 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
SVB Wealth LLC Invests $4.07 Million in Pfizer Inc. $PFE - MarketBeat
Pfizer Says Hympavzi Reduced Bleeds by 93% Compared With On-Demand Treatment in Phase-3 Study - marketscreener.com
Ossiam Boosts Stock Position in Pfizer Inc. $PFE - MarketBeat
StoneX Group Inc. Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Gamco Investors INC. ET AL Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Pfizer Feature in China's Commercial Insurance Innovative Drug Catalog - marketscreener.com
Pfizer (PFE) Reports Positive Phase 3 Results for Hemophilia Tre - GuruFocus
Pfizer’s HYMPAVZI shows superior bleeding control in hemophilia phase 3 study (PFE:NYSE) - Seeking Alpha
Eli Lilly, Pfizer Land on China’s First Private Insurance List - Bloomberg.com
Pfizer (PFE) Reports Positive Phase 3 Study Results for HYMPAVZI - GuruFocus
Autism Spectrum Disorder Market to Reach USD 4.07 Billion by 2033, Driven by Rising Awareness, Early Diagnosis & Advances in Personalized Therapeutics | SNS Insider - GlobeNewswire Inc.
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Pfizer (PFE) Stock; Rises on Strong Dividend Yield and Low Valuation Debate - CoinCentral
Federated Hermes Inc. Raises Stock Position in Pfizer Inc. $PFE - MarketBeat
Eli Lilly, Pfizer land on China’s first private insurance list - The Edge Malaysia
Eli Lilly, Pfizer Secure Inclusion in Chinese Private Health Insurance Catalog - marketscreener.com
Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and Adolescents - marketscreener.com
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue - Yahoo Finance
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
US717081FH1 Bond Price and Chart — DUS:US717081FH1 - TradingView
Pfizer Inc. $PFE Holdings Lowered by Panagora Asset Management Inc. - MarketBeat
Cresset Asset Management LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
Can Pfizer’s Recent Recovery Signal a Long Term Value Opportunity in 2025? - Yahoo Finance
1832 Asset Management L.P. Has $4.89 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Secures Long-Term Capital with $1.25 Billion Bond Offering - AD HOC NEWS
GSK takes over entire building in Cambridge - The Business Journals
Sandoz, Pfizer Denied Bid to End Generic Drug Price-Fixing Case - Bloomberg Law News
2 Headwinds Facing Pfizer Stock Going Into 2026 - Finviz
Pfizer: The Market Is Still Wrong About It (NYSE:PFE) - Seeking Alpha
3 Reasons PFE is Risky and 1 Stock to Buy Instead - Finviz
Baird Financial Group Inc. Sells 406,942 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Stock Holdings Cut by Amundi - MarketBeat
How Does Pfizer Stock Stack Up Against Its Peers? - Trefis
Pfizer Inc. (PFE): A Bull Case Theory - Insider Monkey
Is Pfizer Stock A Buy After It Clinches The $10 Billion Takeover Of Metsera? - Investor's Business Daily
Pharmaceutical Marketing Industry Trends and Emerging Opportunities 2025-2032 Featuring Syneos Health, McCann Health, Amgen, AXPIRA, Pfizer and MoreResearchAndMarkets.com - The AI Journal
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Bio/Pharmaceutical Outsourcing Report, October 2025Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing - Yahoo Finance
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025) - 24/7 Wall St.
Pfizer Inc. $PFE Stock Holdings Cut by Invesco Ltd. - MarketBeat
Could This Fuel The Next Surge in Pfizer Stock - Trefis
Pharmacy Market size to cross $3.4 Trillion by 2035 | Pfizer Inc., - openPR.com
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
Jim Cramer on Pfizer: "I would hold on to it" - MSN
Jim Cramer on Pfizer: “I Would Hold on to It” - Insider Monkey
Jim Cramer on Pfizer: "I Would Hold on to It" - Finviz
Does PADCEV Keytruda Bladder Cancer Win Reshape The Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025) - ts2.tech
Pfizer : November Social Media Round-Up—Third-Quarter Earnings, Metsera Acquisition, and MoreUpdates & StatementsAlbert BourlaArtificial IntelligenceBusinessCancerHealth Equity - MarketScreener
A Decade of Rewards: $68 Bil From Pfizer Stock - Trefis
Antiemetics Market Size, Forecast 2031 by Key Companies- - openPR.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Pfizer price leans on SMA supportForecast today03-12-2025 - Economies.com
Pfizer Inc (NYSE:PFE) S&P 500 Today Indicates Stable Clinical Demand - Kalkine Media
Pfizer Partner 3SBio To Raise $400 Million In Stock Sale - Forbes
MVP: Williams & Connolly's David M. Krinsky - Law360
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure - sharewise.com
Assessing Pfizer's (PFE) Valuation After Recent Share Price Rebound - Yahoo Finance
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
0.32%
1.61%
자본화:
|
볼륨(24시간):